Main menu

London Calling 2023: Potential use of nanopore sequencing in clinical cancer genomics

Advances in sequencing technologies have transformed our understanding of cancer and ushered in a new era for cancer research. The Personalized OncoGenomics (POG) program is a prospective precision medicine initiative integrating whole-genome and transcriptome analysis (WGTA) into the clinical care of people with advanced cancers in British Columbia, Canada. In a sub-study of our larger cohort, we performed long-read Oxford Nanopore sequencing on 178 patient’s samples, in order to address some limitations we have noted with short-read sequencing. Comparison of these data sets has demonstrated situations where we now plan to apply nanopore sequencing prospectively within POG.

resources.authors: Janessa Laskin

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms, conditions and policies Modern slavery policy Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag